-
A Drug Hunter's Perspective on Patent Strategy
Before turning to law, Deborah spent years in drug discovery as a medicinal chemist. She brings that scientific depth to a pragmatic, results-oriented practice, aligning IP strategy with each client’s R&D milestones and business objectives, and designing patent strategy around the science, financing, regulatory, and competitive realities each company is navigating.
-
IP Counsel from Company Creation Through Exit
Deborah advises clients from platform technology development through FDA approval, commercialization, and acquisition, including counsel to Nerio Therapeutics through its $1.3 billion acquisition by Boehringer Ingelheim.
-
Trusted by Growth-Stage Biotech and Its Investors
Deborah has guided clients through IPOs, reverse mergers, and other growth financings, and represents leading venture investors, including Frazier Healthcare Partners, General Atlantic, and RA Capital Management, on IP diligence for their investments.
Deborah Smith leads Wilson Sonsini’s Patents and Innovations practice in Southern California. She advises high-growth biotechnology and pharmaceutical companies and their investors on IP strategy across the full product lifecycle—from platform development through drug approval, commercialization, and exit—spanning modalities including small molecules, ADCs, degraders, molecular glues, peptides, nucleic acid therapeutics, biologics, and protein conjugates. Her work spans patent strategy, portfolio development, IP due diligence, and IP matters tied to regulatory approval, as well as transactional matters including buy-side and sell-side M&A, licensing, financings, IPOs, and reverse mergers.
Before turning to law, Deborah spent several years as a medicinal chemist at Johnson & Johnson Pharmaceutical Research & Development, designing and advancing small molecule drug candidates. That experience continues to shape her practice today, giving her a scientist’s fluency with the R&D process and grounding her strategic advice in the realities of how a program develops. She holds a Ph.D. in organic chemistry from the University of California, Irvine, and completed postdoctoral research at Columbia University. She has co-authored multiple scientific publications and book chapters and is a co-inventor on several U.S. patents.
Deborah is just as invested in the next generation of the practice as she is in her clients’ success. She serves on the firm’s Membership Nominating Committee, co-chairs the firm’s hiring committee and the Women of Wilson committee, and regularly mentors associates and patent agents across the practice.
Deborah Smith leads Wilson Sonsini’s Patents and Innovations practice in Southern California. She advises high-growth biotechnology and pharmaceutical companies and their investors on IP strategy across the full product lifecycle—from platform development through drug approval, commercialization, and exit—spanning modalities including small molecules, ADCs, degraders, molecular glues, peptides, nucleic acid therapeutics, biologics, and protein conjugates. Her work spans patent strategy, portfolio development, IP due diligence, and IP matters tied to regulatory approval, as well as transactional matters including buy-side and sell-side M&A, licensing, financings, IPOs, and reverse mergers.
Before turning to law, Deborah spent several years as a medicinal chemist at Johnson & Johnson Pharmaceutical Research & Development, designing and advancing small molecule drug candidates. That experience continues to shape her practice today, giving her a scientist’s fluency with the R&D process and grounding her strategic advice in the realities of how a program develops. She holds a Ph.D. in organic chemistry from the University of California, Irvine, and completed postdoctoral research at Columbia University. She has co-authored multiple scientific publications and book chapters and is a co-inventor on several U.S. patents.
Deborah is just as invested in the next generation of the practice as she is in her clients’ success. She serves on the firm’s Membership Nominating Committee, co-chairs the firm’s hiring committee and the Women of Wilson committee, and regularly mentors associates and patent agents across the practice.
- J.D., University of San Diego School of LawSumma Cum Laude
- Ph.D., Organic Chemistry, University of California, IrvineRecipient, Roche Excellence in Chemistry Award; Johnson & Johnson Graduate Fellowship in Synthetic Organic Chemistry
- B.S., Microbiology, Colorado State UniversityUniversity Honors Scholar, Distinguished Scholars Award, Phi Beta Kappa, Minor in Chemistry
- Recognized among San Diego Business Journal's 2025 "Leaders of Influence in Law"
- Named to the 2025 and 2026 Lawdragon “500 X – The Next Generation” lists
- State Bar of California
- U.S. Patent and Trademark Office
- J.D., University of San Diego School of LawSumma Cum Laude
- Ph.D., Organic Chemistry, University of California, IrvineRecipient, Roche Excellence in Chemistry Award; Johnson & Johnson Graduate Fellowship in Synthetic Organic Chemistry
- B.S., Microbiology, Colorado State UniversityUniversity Honors Scholar, Distinguished Scholars Award, Phi Beta Kappa, Minor in Chemistry
- Recognized among San Diego Business Journal's 2025 "Leaders of Influence in Law"
- Named to the 2025 and 2026 Lawdragon “500 X – The Next Generation” lists
- State Bar of California
- U.S. Patent and Trademark Office
Select IP Matters
- Taiho Pharmaceutical’s $1.1 billion acquisition of Araris Biotech
- Enlaza Therapeutics’ $2 billion license and collaboration agreement with Vertex Pharmaceuticals
- Nerio Therapeutics’ $1.3 billion acquisition by Boehringer Ingelheim
- Alterome Therapeutics’ $132 million Series B financing
- Forward Therapeutics’ $50 million Series A financing
- Lengo Therapeutics’ acquisition by Blueprint Medicines
- LENZ Therapeutics’ FDA approval of VIZZ® (aceclidine)
- Phathom Pharmaceuticals’ FDA approval of Voquezna® (vonaprazan)
- Delix Therapeutics’ $70 million Series A financing
- Sudo Biosciences’ $116 million (upsized to $147 million) Series B financing
- Tempest Therapeutics’ reverse merger with Millendo Therapeutics
- IP counsel to Frazier Lifesciences Acquisition Corp. in its business combination with NewAmsterdam Pharma
- IP counsel to LifeSci Acquisition Corp. in its business combination with Vincerx Pharma
- Initial public offerings for ORIC Pharmaceuticals, Kinnate Biopharma, Erasca, Phathom Pharmaceuticals, Belite Bio, Boundless Bio, and Odyssey Therapeutics
- IP diligence for Frazier Healthcare Partners, General Atlantic, RA Capital Management, Novo Holdings, Foresite Capital, Versant Venture Capital, Taiho Ventures, and Avalon BioVentures, among other venture and investment funds
Select IP Matters
- Taiho Pharmaceutical’s $1.1 billion acquisition of Araris Biotech
- Enlaza Therapeutics’ $2 billion license and collaboration agreement with Vertex Pharmaceuticals
- Nerio Therapeutics’ $1.3 billion acquisition by Boehringer Ingelheim
- Alterome Therapeutics’ $132 million Series B financing
- Forward Therapeutics’ $50 million Series A financing
- Lengo Therapeutics’ acquisition by Blueprint Medicines
- LENZ Therapeutics’ FDA approval of VIZZ® (aceclidine)
- Phathom Pharmaceuticals’ FDA approval of Voquezna® (vonaprazan)
- Delix Therapeutics’ $70 million Series A financing
- Sudo Biosciences’ $116 million (upsized to $147 million) Series B financing
- Tempest Therapeutics’ reverse merger with Millendo Therapeutics
- IP counsel to Frazier Lifesciences Acquisition Corp. in its business combination with NewAmsterdam Pharma
- IP counsel to LifeSci Acquisition Corp. in its business combination with Vincerx Pharma
- Initial public offerings for ORIC Pharmaceuticals, Kinnate Biopharma, Erasca, Phathom Pharmaceuticals, Belite Bio, Boundless Bio, and Odyssey Therapeutics
- IP diligence for Frazier Healthcare Partners, General Atlantic, RA Capital Management, Novo Holdings, Foresite Capital, Versant Venture Capital, Taiho Ventures, and Avalon BioVentures, among other venture and investment funds
Select Speaking Engagements
- Panelist, “Biotech’s New Playbook: Spinouts and Optionality,” Wilson Sonsini forum, San Diego, May 14, 2026
- Co-presenter, “The IP ABCs of ADCs,” Drug Hunter Flash Talk webinar, 2026
- Presenter, “IP Strategies for Protecting Formulation Technologies and Compositions,” PBSS Workshop: Small-Molecule Formulation for Discovery & Early Development, 2025
- Council Member, Springboard Enterprises Healthcare & Technology Accelerator Program; opening remarks, Accelerator Showcase, J.P. Morgan Healthcare Conference, January 2025
- Moderator, “Trends in Venture Investing” VC panel, Biocom Global Life Science Partnering & Investor Conference, 2023
- Co-presenter with D.K. Wiener and J.P. Edwards, "Tricyclic Histamine H4Receptor Antagonists," presented at the General Poster Session at the 239th ACS National Meeting, poster MEDI-521, San Francisco, California, March 2010
Select Publications
- Co-author, "Continued Scrutiny of Genus Claims: The Written Description and Enablement Requirements for Broad and Previously Undisclosed Subgenera," Wilson Sonsini Alert, December 22, 2025
- Co-author, "Duties of Disclosure and Reasonable Inquiry Before the USPTO May Include Communications with the FDA and Other Government Agencies," Wilson Sonsini Alert, August 25, 2022
- Co-author with M.E. Pulling and J.R. Norton, "Tin-Free and Catalytic Radical Cyclizations," 129(4) Journal of the American Chemical Society 770-771, 2007
- Co-author with S.R. Shenoy and K.A. Woerpel, "Nucleophilic Additions of Trimethylsilyl Cyanide to Cyclic Oxocarbenium Ions: Evidence for the Loss of Stereoselectivity at the Limits of Diffusion Control," 128(26) Journal of the American Chemical Society 8671-8677, 2006
- Co-author with K.A. Woerpel, "Using Stereoelectronic Effects to Explain Selective Reactions of 4-Substituted Five-Membered Ring Oxocarbenium Ions," 6(12) Organic Letters 2063-2066, 2004
- Co-author with M.B. Tran and K.A. Woerpel, "Nucleophilic Additions to Fused Bicyclic Five-Membered Ring Oxocarbenium Ions: Evidence for Preferential Attack on the Inside Face," 125(46) Journal of the American Chemical Society 14149-14152, 2003
Select Speaking Engagements
- Panelist, “Biotech’s New Playbook: Spinouts and Optionality,” Wilson Sonsini forum, San Diego, May 14, 2026
- Co-presenter, “The IP ABCs of ADCs,” Drug Hunter Flash Talk webinar, 2026
- Presenter, “IP Strategies for Protecting Formulation Technologies and Compositions,” PBSS Workshop: Small-Molecule Formulation for Discovery & Early Development, 2025
- Council Member, Springboard Enterprises Healthcare & Technology Accelerator Program; opening remarks, Accelerator Showcase, J.P. Morgan Healthcare Conference, January 2025
- Moderator, “Trends in Venture Investing” VC panel, Biocom Global Life Science Partnering & Investor Conference, 2023
- Co-presenter with D.K. Wiener and J.P. Edwards, "Tricyclic Histamine H4Receptor Antagonists," presented at the General Poster Session at the 239th ACS National Meeting, poster MEDI-521, San Francisco, California, March 2010
Select Publications
- Co-author, "Continued Scrutiny of Genus Claims: The Written Description and Enablement Requirements for Broad and Previously Undisclosed Subgenera," Wilson Sonsini Alert, December 22, 2025
- Co-author, "Duties of Disclosure and Reasonable Inquiry Before the USPTO May Include Communications with the FDA and Other Government Agencies," Wilson Sonsini Alert, August 25, 2022
- Co-author with M.E. Pulling and J.R. Norton, "Tin-Free and Catalytic Radical Cyclizations," 129(4) Journal of the American Chemical Society 770-771, 2007
- Co-author with S.R. Shenoy and K.A. Woerpel, "Nucleophilic Additions of Trimethylsilyl Cyanide to Cyclic Oxocarbenium Ions: Evidence for the Loss of Stereoselectivity at the Limits of Diffusion Control," 128(26) Journal of the American Chemical Society 8671-8677, 2006
- Co-author with K.A. Woerpel, "Using Stereoelectronic Effects to Explain Selective Reactions of 4-Substituted Five-Membered Ring Oxocarbenium Ions," 6(12) Organic Letters 2063-2066, 2004
- Co-author with M.B. Tran and K.A. Woerpel, "Nucleophilic Additions to Fused Bicyclic Five-Membered Ring Oxocarbenium Ions: Evidence for Preferential Attack on the Inside Face," 125(46) Journal of the American Chemical Society 14149-14152, 2003
- Privacy Policy
- Terms of Use
- Accessibility